Arbor Biotechnologies Stock
HealthTechLooking to sell Arbor Biotechnologies stock or options?
Arbor Biotechnologies develops genomic tools aimed at enhancing human health and promoting sustainability. The company's technology leverages AI and machine learning to compile genomic sequence data, optimizing future cycles of treatments for genetic diseases previously deemed incurable. This enables drug developers to perform whole-gene replacements and accurately correct mutations, facilitating treatment for all patients with genetic disorders.
ARCH Venture Partners, TCG Crossover Management, Ally Bridge Group, Illumina Ventures, GreatPoint Ventures, Deep Track Capital, ArrowMark Partners, T. Rowe Price Group, Tao Capital Partners, MIT Startup Exchange, Piper Sandler, Janus Henderson Investors, Ono Venture Investment, Woodline Partners, Temasek Holdings, S32, Surveyor Capital, Faridan, Vertex Pharmaceuticals, Ridgeback Capital, Logos Capital, Alexandria Venture Investments.